CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 201 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02333383
NCT02333383N/ACompleted
CompareCT.gov

A Prospective, Mono-Country, Multi-Center Study to Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis Patients on Adalimumab Therapy

AbbVie·observational·Posted Jan 7, 2015·Updated Jan 15, 2019

In Brief

An observational study evaluating Adalimumab for Ankylosing Spondylitis. Completed, enrolled 201 participants.

Detailed Summary

This was a prospective mono-country, multi-center study of the frequency of extra-axial manifestations (EAMs) in Ankylosing Spondylitis (AS) participants treated with adalimumab in routine clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 7, 2015
Enrollment StartDec 31, 2014
Primary CompletionAug 8, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.5 years ago

Interventions

Adalimumabdrug

Adalimumab pre-filled syringe, administered by subcutaneous injection